| | | | --- | --- | | **Target** | CDK4/6 | | **Disease** | breast cancer | | **Date Generated** | 2026-03-04 | | **Total Papers** | 4 | | **Date Range** | 2023-2024 | --- ## Summary This report extracts and synthesizes preclinical experiment details from 4 papers studying **CDK4/6** in **breast cancer**. ### Experiment Type Breakdown | Type | Count | Percentage | | --- | --- | --- | | In vitro only | 1 | 25.0% | | In vivo only | 1 | 25.0% | | Both | 1 | 25.0% | | Unclassified | 1 | 25.0% | --- ## Narrative Synthesis ### Evidence Landscape Across 4 papers published from 2023–2024, the preclinical evidence is spanning both in vitro and in vivo approaches. Studies employed 4 unique cell line(s) and 2 animal model type(s). ### Therapeutic Direction - **Inhibit CDK4/6.** 3 of 4 papers test inhibition or blockade of CDK4/6, and findings predominantly report anti-tumor effects (reduced growth, suppressed proliferation, induced apoptosis). This suggests CDK4/6 inhibition is the therapeutically productive direction. - Modality breakdown: 3 papers test inhibition/blockade, 1 test activation/overexpression. ### Convergent Findings - Findings predominantly report inhibitory/suppressive effects (8 of 9 directional findings, 89%), suggesting convergent evidence for negative regulation of the target pathway or disease phenotype. ### Divergent Findings - No clear directional disagreements detected between studies. Note that keyword-based analysis cannot capture subtle methodological differences or contradictions in effect magnitude. ### Evidence Gaps - No patient-derived xenograft (PDX) models reported. PDX models preserve patient tumor heterogeneity and are considered more clinically predictive than established cell line xenografts. - No pharmacokinetic (PK) data reported across in vivo studies. - Most recent paper is from 2024. No publications found in 2025–2026, suggesting research activity may have declined. --- ## In Vitro Experiments ### Most Common Cell Lines | Rank | Cell Line | Papers | | --- | --- | --- | | 1 | BT-549 | 1 | | 2 | MDA-MB-231 | 1 | | 3 | MiaPaCa-2 | 1 | | 4 | PANC-1 | 1 | ### Most Common Assay Types | Rank | Assay Type | Papers | | --- | --- | --- | | 1 | apoptosis | 2 | | 2 | flow\_cytometry | 2 | | 3 | viability | 2 | | 4 | proliferation | 1 | | 5 | protein\_analysis | 1 | | 6 | gene\_expression | 1 | | 7 | migration\_invasion | 1 | --- ## In Vivo Experiments ### Animal Model Types | Rank | Model Type | Papers | | --- | --- | --- | | 1 | xenograft | 1 | | 2 | syngeneic | 1 | ### Endpoints Measured | Rank | Endpoint | Papers | | --- | --- | --- | | 1 | tumor\_growth | 3 | | 2 | toxicity | 2 | | 3 | histology | 1 | | 4 | imaging | 1 | | 5 | survival | 1 | --- ## Papers with Both In Vitro and In Vivo Data 1 paper reports both in vitro and in vivo experiments: 1. **[CDK4/6 inhibition suppresses triple-negative breast cancer cell proliferation in vitro and in vivo](https://pubmed.ncbi.nlm.nih.gov/MOCK001/)** - Smith J, Jones A, Wang L et al.... (2024) — [PMID: MOCK001](https://pubmed.ncbi.nlm.nih.gov/MOCK001/) - Cell lines: BT-549; MDA-MB-231 - Assays: apoptosis; flow\_cytometry; proliferation; protein\_analysis; viability - Models: xenograft - Endpoints: histology; toxicity; tumor\_growth --- ## Publication Timeline | Year | Papers | | --- | --- | | 2023 | 1 | | 2024 | 3 | --- ## Per-Paper Extraction Details See `experiment_extraction.csv` for full per-paper details. --- ## Full-Text Insights *Pending: Read full text for top papers and replace this section with per-paper findings. See references/full-text-enrichment-guide.md.* --- ## References 1. Smith J, Jones A, Wang L et al.. [CDK4/6 inhibition suppresses triple-negative breast cancer cell proliferation in vitro and in vivo](https://pubmed.ncbi.nlm.nih.gov/MOCK001/). *Cancer Research (2024)*. [PMID: MOCK001](https://pubmed.ncbi.nlm.nih.gov/MOCK001/) | [DOI: 10.1234/mock001](https://doi.org/10.1234/mock001) 2. Chen X, Kim Y, Park S. [KRAS G12C inhibitor demonstrates anti-tumor activity in pancreatic cancer cell lines](https://pubmed.ncbi.nlm.nih.gov/MOCK002/). *Molecular Cancer Therapeutics (2023)*. [PMID: MOCK002](https://pubmed.ncbi.nlm.nih.gov/MOCK002/) | [DOI: 10.1234/mock002](https://doi.org/10.1234/mock002) 3. Rodriguez M, Taylor B, Wilson K. [PD-L1 blockade enhances anti-tumor immunity in syngeneic mouse models of NSCLC](https://pubmed.ncbi.nlm.nih.gov/MOCK003/). *Journal of Immunotherapy (2024)*. [PMID: MOCK003](https://pubmed.ncbi.nlm.nih.gov/MOCK003/) | [DOI: 10.1234/mock003](https://doi.org/10.1234/mock003) 4. Lee H, Brown D. [Computational analysis of drug resistance mechanisms in breast cancer](https://pubmed.ncbi.nlm.nih.gov/MOCK004/). *Bioinformatics (2024)*. [PMID: MOCK004](https://pubmed.ncbi.nlm.nih.gov/MOCK004/) | [DOI: 10.1234/mock004](https://doi.org/10.1234/mock004) --- *Report generated by literature-preclinical skill.*